Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lung cancer drug aims to match Keytruda's success

NCT ID NCT06939595

Ongoing Disease control Sponsor: Celltrion Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a new drug called CT-P51 works as well as the established immunotherapy Keytruda for people with advanced non-squamous non-small cell lung cancer that has not been treated before. All participants also receive standard chemotherapy. The study compares how many patients' tumors shrink or disappear with each treatment combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CT-P51 (a biosimilar to Keytruda)
What this could lead to
If CT-P51 works as well as Keytruda, it could offer a more affordable treatment option for people with this type of lung cancer.
What could go wrong
This is an early comparison study. CT-P51 may not be as effective or safe as Keytruda, and results may not apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • ltd "Institute of Clinical Oncology"

    Tbilisi, Georgia

More trials for these conditions

Other studies related to the condition(s) this trial covers.